Clinical impact of low bone mineral density in patients with colorectal cancer liver metastasis undergoing hepatectomy.

Clinical impact of low bone mineral density in patients with colorectal cancer liver metastasis undergoing hepatectomy.

Show other versions (1)

<h4>Background</h4>This study aimed to elucidate the clinical impact of osteopenia on the recurrence of colon cancer liver metastases.<h4>Methods</h4>Patients with colon cancer liver metastases (N = 186) undergoing hepatectomy at Jichi Medical University Hospital between Marc...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuichi Aoki, Atsushi Miki, Yasunaru Sakuma, Jun Watanabe, Takehiro Kagaya, Makiko Tahara, Takumi Teratani, Kazuhiro Endo, Hideki Sasanuma, Wataru Nishimura, Hisanaga Horie, Joji Kitayama, Naohiro Sata, Hironori Yamaguchi
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0324719
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<h4>Background</h4>This study aimed to elucidate the clinical impact of osteopenia on the recurrence of colon cancer liver metastases.<h4>Methods</h4>Patients with colon cancer liver metastases (N = 186) undergoing hepatectomy at Jichi Medical University Hospital between March 2006 and March 2020 were examined retrospectively. Computed tomography (CT) scans on the 11th vertebra within 3 months of surgery assessed bone mineral density (BMD). Age-adjusted BMD determined osteopenia presence. Kaplan-Meier method with a log-rank test estimated survival. Factors associated with survival were assessed using Cox's proportional hazards model after adjustment for confounders.<h4>Results</h4>Patients with osteopenia had shorter overall (p = 0.0001; 5-year overall survival, 51.8% vs 81.8%) and recurrence-free survival (p = 0.0008, 5-year recurrence-free survival: 26.3% vs 51.5%) than BMD-normal patients. In multivariable analysis, the risk factor for overall survival was osteopenia (Hazard ratio (HR) 3.79, 95% confidence interval (CI) 2.09-6.87, p = 0.001). Risk factors for recurrence were chemotherapy (HR 1.92, 95%CI 1.12-3.30, p = 0.002), tumor number (HR 1.51, 95%CI 1.02-2.27, p = 0.04), and osteopenia (HR 2.18, 95%CI 1.46-3.24 p = 0.001). Patients with osteopenia are more likely to develop lung metastases, and BMD-value reduction associated with KRAS mutation.<h4>Conclusion</h4>Osteopenia may have prognostic significance in patients with liver metastases colorectal cancer.
ISSN:1932-6203

Similar Items